Novartis Sets Out New Company Structure, Integrates Business Units
04 Abril 2022 - 1:06AM
Noticias Dow Jones
By Cecilia Butini
Novartis AG said Monday that it is integrating some of its
business units into a new company structure to boost growth and
cost savings.
The Swiss pharma company said it is integrating its
pharmaceuticals and oncology units into an Innovative Medicines
unit, which will have separate commercial organizations in the U.S.
and internationally.
The company said it is creating a new strategy-and-growth
business that will combine corporate strategy, research and
development, and business development. The unit is meant to drive
Novartis's growth strategy and provide opportunities to strengthen
its pipeline, it said.
Novartis said it would also create a new operations unit by
combining its Technical Operations and Customer and Technology
Solutions units.
As a result of the new structure, Novartis expects to save $1
billion in expenses by 2024. It also foresees 4% sales growth by
2026 and expects to deliver the high end of its margin guidance for
Innovative Medicines.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 04, 2022 01:51 ET (05:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
